AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.33
+3.76%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$26.48
From 52W high−31.09%
Volume1.38M
Market cap$3.43B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$26.48
From 52W high
−31.09%
Volume
1.38M
Market cap
$3.43B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−21.3x
P/E (TTM)
—
RSI (14)
38.7
MomentumView details →
1D Return
+3.76%
YTD Return
+121.18%
SummaryUpdated Jun 1, 2026
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in January 2022 and initially gained prominence with its ALS drug RELYVRIO, which received FDA approval in September 2022. However, following disappointing Phase 3 trial results, Amylyx voluntarily withdrew RELYVRIO from the market in April 2024. The company has since pivoted to focus on developing treatments for rare neurodegenerative and endocrine disorders, with its lead asset avexitide targeting post-bariatric hypoglycemia.
Similar companies
Latest newsMore news →
Amylyx Pharmaceuticals signed a manufacturing and supply agreement with Bachem Americas for the supply of avexitide drug substance, with minimum purchase quantities beginning in 2028 and an initial five-year term.41d agoAmylyx Pharmaceuticals announced the commencement of an underwritten public offering of $350.0 million of its common stock, with an option for underwriters to purchase up to an additional $52.5 million of shares.62d agoAmylyx Pharmaceuticals announced positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia, meeting its primary endpoint with a 55% reduction in severe hypoglycemic events.62d ago